Welcome to our dedicated page for Tenon Medical SEC filings (Ticker: TNON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tenon Medical, Inc. filings document its medical-device business, public securities, and material events tied to sacroiliac joint treatment products. Current Reports on Form 8-K cover financial results, unaudited revenue releases, FDA-cleared product updates, and corporate communications related to the Catamaran System and SImmetry® portfolio.
The filing record also discloses securities purchase agreements, senior convertible notes, private placements of common stock and warrants, restricted stock unit grants under the 2022 Equity Incentive Plan, annual meeting voting matters, Nasdaq listing-compliance notices, and amended acquisition disclosures with financial statements and pro forma information for the SiVantage asset acquisition.
Tenon Medical director Kristine M Jacques converted 10,147 restricted stock units, granted on October 13, 2025, into 10,147 shares of common stock on July 31, 2026. Following this RSU conversion, she directly holds 20,876 shares of Tenon Medical common stock.
Tenon Medical, Inc. director Ivan Howard exercised 10,732 restricted stock units on July 31, 2026, converting them into 10,732 shares of common stock at $0.00 per share. The RSUs were fully converted, and his direct ownership increased to 19,194 common shares after the transaction.
Tenon Medical, Inc. director Stephen Hochschuler converted 10,732 restricted stock units granted on October 13, 2025 into 10,732 shares of common stock on July 31, 2026 at a stated price of $0.00 per share. After the conversion, he directly holds 18,670 shares of Tenon Medical common stock and no remaining units from this grant.
Tenon Medical director Richard Ferrari converted 64,479 restricted stock units into 64,479 shares of common stock on July 31, 2026. Each unit represented a contingent right to receive one share. After this settlement, he directly owned 135,243 shares of Tenon Medical common stock.
Tenon Medical, Inc. Chief Financial Officer Kevin Williamson reported equity compensation activity and related tax withholding. On July 31, 2026, 58,987 restricted stock units vested and converted into 58,987 shares of common stock. On August 3, 2026, 12,978 common shares were delivered/withheld at $0.198 per share to satisfy tax liabilities arising from this RSU vesting.
Tenon Medical director and Chief Technology Officer Richard Ginn reported the vesting and conversion of 126,577 restricted stock units into the same number of common shares on July 31, 2026, from RSUs granted on October 13, 2025. On August 3, 2026, he sold 44,809 common shares at $0.198 per share to pay tax liability related to this RSU vesting.
Tenon Medical, Inc. reported equity compensation activity by CEO and President Steven M. Foster140,936 Restricted Stock Units (RSUs) that were granted on October 13, 2025 converted into 140,936 shares of common stock, with each RSU representing a contingent right to one share.
In a related transaction on August 3, 2026, 41,788 shares of common stock were disposed of at $0.198 per share. Footnote disclosure states these shares were sold to pay the tax liability associated with the vesting of the RSUs, indicating a tax-withholding disposition rather than an open-market portfolio trade.
Tenon Medical, Inc. reported results of its 2026 Annual Meeting of Stockholders, where holders of 6,471,472 shares of voting stock, representing 52.98% of votes, were present, establishing a quorum. As of the June 8, 2026 record date, voting power included 11,849,674 common shares, 204,159 Series A preferred shares representing 255,184 votes, and 86,454 Series B preferred shares representing 108,074 votes.
Stockholders elected all director nominees—Richard Ferrari, Steven Foster, Richard Ginn, Stephen Hochschuler, MD, Ivan Howard, Kristine Jacques, and Robert Weigle—to serve until the company’s 2026 annual meeting of stockholders. They also approved the auditor appointment, a Reverse Stock Split Proposal, a Debt Financing Proposal, a Future Financing Proposal, and an adjournment proposal, each by a majority of shares represented and entitled to vote.
Tenon Medical, Inc. reported that Nasdaq has notified the company it has regained compliance with the continued listing requirement to maintain at least $2.5 million in stockholders’ equity under Nasdaq Listing Rule 5550(b)(1), known as the Stockholders’ Equity Rule.
Nasdaq’s July 17, 2026 notice was based on Tenon’s July 10, 2026 report stating that the company met this rule following completion of a $4.2 million public offering of common stock and warrants on July 1, 2026. Tenon also notes that if it does not demonstrate compliance when it files its Form 10-Q for the quarter ending September 30, 2026, its common stock may be subject to delisting from Nasdaq, with any such decision subject to appeal.